Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $96.10: Leverage penalty (D/E 1.0): -0.5; Concentration risk — Product: approved medicines.
Mirum Pharmaceuticals is a rare disease biopharma with three approved medicines: Livmarli (maralixibat, for ALGS and PFIC), Cholbam (cholic acid, for bile acid synthesis disorders), and Ctexli (chenodiol, for CTX). It commercializes these products in the US, Canada, and select... Read more
Sell if holding. Multiple concerning factors at $96.10: Leverage penalty (D/E 1.0): -0.5; Concentration risk — Product: approved medicines. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 5.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.50, semi cycle peak clear). Fails on earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductapproved medicines10-K Item 1A: 'The success of our business depends, in part, on our ability to market and sell our approved medicines profitably.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $96.10: Leverage penalty (D/E 1.0): -0.5; Concentration risk — Product: approved medicines. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $90.06. Score 5.8/10, moderate confidence.
Take-profit target: $112.86 (+17.4% upside). Prior stop was $90.06. Stop-loss: $90.06.
Concentration risk — Product: approved medicines; Leverage penalty (D/E 1.0): -0.5; Earnings in 6 days (event risk).
Mirum Pharmaceuticals, Inc. trades at a P/E of N/A (forward -9420.0). TrendMatrix value score: 5.6/10. Verdict: Sell.
17 analysts cover MIRM with a consensus score of 4.3/5. Average price target: $130.
What does Mirum Pharmaceuticals, Inc. do?Mirum Pharmaceuticals is a rare disease biopharma with three approved medicines: Livmarli (maralixibat, for ALGS and...
Mirum Pharmaceuticals is a rare disease biopharma with three approved medicines: Livmarli (maralixibat, for ALGS and PFIC), Cholbam (cholic acid, for bile acid synthesis disorders), and Ctexli (chenodiol, for CTX). It commercializes these products in the US, Canada, and select European markets, while advancing volixibat and brelovitug in clinical trials.